The Vanguard Group, Inc. has recently announced that it has increased stake in Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 2.37%. After grabbing 8.59 million shares, the institutional investor is now in possession of 0.2 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 7.50% having worth around $6.62 million. Moreover, Jacobs Levy Equity Management, In increased its share by 1.68 million to have a control over 2.35 million shares. And Geode Capital Management LLC raised its holdings to 0.15 million shares by acquiring 2.29 million shares or 2.00% of the stake.
Karyopharm Therapeutics Inc (KPTI) concluded trading on 12/21/23 at a closing price of $0.76, with 2.03 million shares of worth about $1.55 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.78% during that period and on Thursday the price saw a gain of about 0.32%. Currently the company’s common shares owned by public are about 113.21M shares, out of which, 106.43M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 9 analysts are covering the KPTI stock and their offered price forecasts bring an average price target of $5.67. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $10.00 and could fall to a lowest price of $3.00. The stock’s current price level is 86.6% above of average price target set by the analysts, while a rise to estimated low would result in gain of 74.67% for the stock. However, touching the estimated high of $10.00 would mean a gain of 92.4% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 38 times over the past 12 months. They bought 813,140 shares in 8 of the transactions. In 30 selling transactions, insiders dumped 152,118 shares.
Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and Vanguard Explorer Fund are the top 3 mutual funds which are holding stakes in Karyopharm Therapeutics Inc Vanguard Total Stock Market ETF is currently holding 3.21 million shares of worth totaling $2.47 million. The company recently came selling -0.2 million shares which brought its stake up to 2.80% of the company’s outstanding shares. iShares Russell 2000 ETF bought 1323.0 shares, after which its hold over company’s outstanding shares expand to 2.35%, leaving 2.69 million shares with the mutual fund that have a worth of about $2.07 million. Vanguard Explorer Fund, after buying 2.26 million shares, have now control over 1.98% of the stake in the company. It holds 0.0 shares of worth $1.74 million.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) started trading at $0.79, above $0.03 from concluding price of the previous day. Stock saw a price change of -9.47% in past 5 days and over the past one month there was a price change of 3.03%. Year-to-date (YTD), KPTI shares are showing a performance of -77.63% which decreased to -74.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.62 but also hit the highest price of $4.87 during that period. The average intraday trading volume for Karyopharm Therapeutics Inc shares is 1.19 million. The stock is currently trading -1.96% below its 20-day simple moving average (SMA20), while that difference is down -10.48% for SMA50 and it goes to -60.50% lower than SMA200.
The Vanguard Group, Inc. acquired 8.59 million shares of Karyopharm Therapeutics Inc having value of about $6.62 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 0.2 million shares in the company valued at close to $151263.56, or have control over 2.37% stake in the company. Karyopharm Therapeutics Inc (NASDAQ: KPTI) currently have 113.21M outstanding shares and institutions hold larger chunk of about 70.83% of that. Holding of mutual funds in the company is about 24.21% while other institutional holders and individual stake holders have control over 46.67% and 13.14% of the stake respectively.
The stock has a current market capitalization of $87.11M and its 3Y-monthly beta is at -0.24. It has posted earnings per share of -$1.32 in the same period. It has Quick Ratio of 4.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KPTI, volatility over the week remained 11.87% while standing at 12.67% over the month.
Analysts are in expectations that Karyopharm Therapeutics Inc (KPTI) stock would likely to be making an EPS of $M-tron Industries, Inc. in the current quarter, while forecast for next quarter EPS is $34.70 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $OPTEC INTERNATIONAL INC which is $SPDR Portfolio Intermediate Ter at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $SPTI in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 43.45% while it is estimated to increase by 24.51% in next year.
Analysts at 9 brokerage firms have issued recommendations for the Karyopharm Therapeutics Inc (KPTI)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.89. Out of those 9 Wall Street analysts, 4 recommended a “Buy” rating, while 3 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on January 19, 2023 offering an Overweight rating for the stock and assigned a target price of $8 to it.
